Nucleolar damage correlates with neurotoxicity induced by different platinum drugs

作者: M J McKeage , T Hsu , D Screnci , G Haddad , B C Baguley

DOI: 10.1054/BJOC.2001.2024

关键词: NeurotoxicitySensory nerveAnatomyPharmacologyCisplatinOrmaplatinSensory neuronCarboplatinBiologyOxaliplatinToxicity

摘要: Platinum-based drugs are very useful in cancer therapy but associated with neurotoxicity the clinic. To investigate mechanism of neurotoxicity, dorsal root ganglia rats treated various platinum were studied. Cell body, nuclear and nucleolar dimensions sensory nerve cells measured to determine morphological toxicity. Sensory conduction velocity was functional After a single dose oxaliplatin (10 mg kg–1), no significant change cell body diameter seen decreased size apparent within few hours treatment. Changes maximal at 24 hours, recovered slowly showed non-linear dependence on (r2= 0.99). Functional toxicity delayed onset until 14 days after eventually 3 months Multiple doses cisplatin, carboplatin, oxaliplatin, R, R -ormaplatin S, S also time-dependent reduction size. A linear correlation obtained between rate during multiple treatment series time taken for development altered 0.86;P< 0.024). Damage nucleolus ganglionic neurons is therefore linked platinum-based drugs, possibly through mechanisms resulting inhibition rRNA synthesis. © 2001 Cancer Research Campaign http://www.bjcancer.com

参考文章(38)
Mark J. McKeage, Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents Humana Press, Totowa, NJ. pp. 251- 275 ,(2000) , 10.1007/978-1-59259-012-4_11
Barajon I, Cavaletti G, Tredici G, Petruccioli Mg, Cece R, An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histology and Histopathology. ,vol. 10, pp. 837- 845 ,(1995)
Mervyn Jones, Frances E. Boxall, Mark J. McKeage, Kenneth R. Harrap, Lack of Neurotoxicity of Oral Bisacetatoamminedichlorocyclohexylamine-platinum(IV) in Comparison to Cisplatin and Tetraplatin in the Rat Cancer Research. ,vol. 54, pp. 629- 631 ,(1994)
Peter J. O'Dwyer, Russell J. Schilder, Frank P. LaCreta, Robert F. Ozols, Raymond P. Perez, Sherri Nash, James M. Brennan, Andre Rogatko, Ceclia McAleer, David Roby, Thomas C. Hamilton, Steven W. Johnson, Robert C. Young, Phase I and Pharmacokinetic Study of Ormaplatin (Tetraplatin, NSC 363812) Administered on a Day 1 and Day 8 Schedule Cancer Research. ,vol. 54, pp. 709- 717 ,(1994)
Shalina Gupta-Burt, Eddie Reed, David Katz, Miriam C. Poirier, Charles L. Litterst, Persistence of Platinum-Ammine-DNA Adducts in Gonads and Kidneys of Rats and Multiple Tissues from Cancer Patients Cancer Research. ,vol. 52, pp. 149- 153 ,(1992)
R W Gregg, J M Molepo, V J Monpetit, N Z Mikael, D Redmond, M Gadia, D J Stewart, Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. Journal of Clinical Oncology. ,vol. 10, pp. 795- 803 ,(1992) , 10.1200/JCO.1992.10.5.795
J L Misset, M Marty, J M Extra, S Brienza, Pharmacokinetics and safety profile of oxaliplatin. Seminars in Oncology. ,vol. 25, pp. 13- 22 ,(1998)
Daniel Fink, Stephen B. Howell, How Does Cisplatin Kill Cells Humana Press, Totowa, NJ. pp. 149- 167 ,(2000) , 10.1007/978-1-59259-012-4_7
Harold C. Harder, Barnett Rosenberg, Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cellsin vitro International Journal of Cancer. ,vol. 6, pp. 207- 216 ,(1970) , 10.1002/IJC.2910060207
R. F. Ozols, Optimum chemotherapy for ovarian cancer. International Journal of Gynecological Cancer. ,vol. 10, pp. 33- 37 ,(2000) , 10.1046/J.1525-1438.2000.99508.X